Collaboration Agreement to Share Best Practices for Improved Cancer Treatment

By MedImaging International staff writers
Posted on 23 Mar 2015
The World Molecular Imaging Society (WMIS; Culver City, CA, USA) and the US National Cancer Institute (NCI; Rockville, MD, USA) have announced that they will begin collaborating to promote best practices for the treatment of cancer and other diseases. The clinical goals of the collaboration are to establish effective mouse/human co-clinical therapy and prevention trials.

The two institutes will cooperate on best practices for co-clinical trials of combination therapy in patients and mice, and for quantitative imaging and imaging protocols for mouse and human-in-mouse models of appropriate genotypes representing patients. The collaboration should improve the correlation of prospective and/or retrospective clinical trial data, with the results from the mouse models.

Hedvig Hricak MD, PhD, chairman, department of radiology, Memorial Sloan-Kettering Cancer, member of WMIS, said, "Molecular imaging and the emerging field of theranostics are essential to the successful implementation of precision medicine. The World Molecular Imaging Society, with its international forum for discussing all aspects of molecular imaging and related fields, is in a unique position to take the lead in global discussion, innovation and scientific collaboration, from preclinical studies to first-in-human imaging trials."

Related Links:

WMIS
NCI



Latest Nuclear Medicine News